News | Radiopharmaceuticals and Tracers | October 28, 2016

New Report Finds U.S. Supply of Critical Medical Isotope Vulnerable

Report documents status of transition from high-enriched to low-enriched uranium targets during production

NAS report, National Academies of Sciences Engineering and Medicine, Mo-99 production, highly enriched uranium, HEU, SNMMI

October 28, 2016 — The National Academies of Sciences, Engineering, and Medicine (NAS) have released a report on the state of molybdenum-99 (Mo-99) production, its utilization in medicine, and progress toward eliminating the use of highly enriched uranium (HEU) during production.

The report was mandated by the American Medical Isotopes Production Act of 2012 and says, “The committee judges that there is a substantial (>50 percent) likelihood of severe molybdenum-99/technetium-99m supply shortages after October 2016, lasting at least until current global suppliers complete their planned capacity expansions.”

Mo-99 is used to produce Tc-99m, the most commonly used radioisotope worldwide (about half in the United States). The production and supply of radioisotopes iodine-131 (I-131) and xenon-133 (Xe-133) are also a concern.

Shortages of Mo-99 in recent years, due to reliance on aging reactors outside the United States, have led to major efforts around the globe to ensure a reliable supply. Since a major shortage of Mo-99 occurred in 2009, there has been pessimism about meeting future needs for Tc-99m.

The NAS report points out that 75 percent of the global supply of Mo-99 for medical use is produced using HEU targets; the remaining 25 percent is produced with low enriched uranium (LEU targets).

The U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) is providing matching funding opportunities for research and development of domestic Mo-99 production methods that do not use HEU. Four NNSA-supported projects are currently underway, and each project is intended to supply half or more of U.S. needs. However, the report states that substantial domestic supplies are unlikely to be available before 2018 due to technical, financial, regulatory and market challenges.

The study recommends that the U.S. government continue to work with the Canadian government to ensure that a plan is in place to restart Canadian supply if needed. Canada has said it will keep its reactor on stand-by until the end of March 2018, when it will shut down permanently.

Progress is being made toward eliminating the use of HEU for medical isotope production; global Mo-99 suppliers have committed to eliminating HEU use in reactor targets and medical isotope production facilities, and financial support from NNSA and technical support from U.S. national laboratories are facilitating domestic production efforts. However, the continued availability of Mo-99 produced with HEU is an impediment. Companies using LEU find themselves at a competitive disadvantage.

The NAS report recommends that the U.S. government and others should take additional actions to promote the wider use of non-HEU produced Mo-99/Tc-99m.

The report outlines additional steps that could be taken:

  • The Centers for Medicare & Medicaid Services (CMS) could continue to offer the $10 add-on reimbursement for Tc-99m from non-HEU sources until HEU sources are no longer available in the U.S. CMS could also accelerate the retrospective analysis of the costs of medical procedure that utilize Tc-99m from non-HEU sources;
  • NNSA could examine options to eliminate the availability of HEU targets for Mo-99 production to shorten the transition process. It might buy back U.S. origin HEU in raw or target form from global Mo-99 suppliers, once production with LEU targets is well established;
  • Technetium generator manufacturers and nuclear pharmacies could continue efforts to further increase the use of Mo-99 from non-HEU sources; and
  • The U.S. Congress could restrict, or place financial penalties on, the import of Mo-99 produced with HEU targets (once non-HEU sources are widely available).

Society of Nuclear Medicine and Molecular Imaging (SNMMI) President Sally W. Schwarz, MS, RPh, BCNP, professor of radiology at Washington University School of Medicine in St. Louis, agrees in general with the report’s assessment and also noted, “Development of these new, non-HEU production methods is costly, even when shared with governments. It will take time and incremental changes to reach a balance point of fair reimbursement for increased costs for all members of the supply chain including Mo-99 producers, generator manufacturers, nuclear pharmacies, hospitals and patients.”

Schwarz cautioned that the potential for short-term shortages is a real concern, but the global Mo-99 producers, processors and generator manufacturers, working with AIPES, will strive to manage any interim shortage problems that might occur.

She is optimistic overall about Mo-99/Tc-99m production through non-HEU means and the development of a domestic source of Mo-99. “The innovative, safer production methods and facilities that will be coming online over the next few years will certainly help ensure a safe, reliable supply of Mo-99.”

Read the 2017 article "FDA Clears Path for First Domestic Supply of Tc-99m Isotope." 
 

For more information: www.snmmi.org

Related Content

Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
The Siemens Biograph Vision PET-CT system was released in mid-2018.

The Siemens Biograph Vision PET-CT system was released in mid-2018.

Feature | Nuclear Imaging | September 07, 2018 | By Dave Fornell
Nuclear imaging technology for both single photon emission computed tomography (SPECT) and positron emission tomography...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Brain Study of 62,454 Scans Identifies Drives of Brain Aging
News | SPECT Imaging | August 27, 2018
In the largest known brain imaging study, scientists from five institutions evaluated 62,454 brain single photon...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Novel PET Imaging Method Could Track and Guide Type 1 Diabetes Therapy
News | PET Imaging | August 03, 2018
Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...